All In Biotech

Drug Trial Radar · NCT02661503

HD21 for Advanced Stages

HD21 for Advanced Stages Treatment Optimization Trial in the First-line Treatment of Advanced Stage Hodgkin Lymphoma; Comparison of 6 Cycles of Escalated BEACOPP With 6 Cycles of BrECADD

Last checked: Nov 20, 2026Latest source record: May 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 1,500 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,500

Actual

Start

Jul 2016

Primary completion

Dec 2022

Study completion Sep 2025

Sponsor

Lead sponsor
University of CologneAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 22, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary objective of the trial is to demonstrate non-inferior efficacy of six cycles of BrECADD compared to six cycles of escalated BEACOPP, each followed by radiotherapy to PET-positive residual lesions ≥2.5 cm, in terms of progression free survival (efficacy objective). If non-inferior efficacy can be shown, the co-primary objective is to further demonstrate reduced toxicity of the BrECADD treatment compared to the escalated BEACOPP treatment measured by treatment related morbidity (TRMorbidity objective).

Conditions

  • Classical Hodgkin Lymphoma

Interventions

  • BleomycinDrug

  • EtoposideDrug

  • DoxorubicinDrug

  • CyclophosphamideDrug

  • VincristineDrug

  • ProcarbazineDrug

  • PrednisoneDrug

  • Brentuximab VedotinDrug

  • DacarbazineDrug

  • DexamethasoneDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free SurvivalTime frame: 5 years
  2. Treatment Related MorbidityTime frame: during 6 cycles of chemotherapy (21-day cycles)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospital of Cologne

    Cologne, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.